Healthcare Master Fun Broadfin Sells 890,516 Shares of Aratana Therapeutics, Inc. (PETX) Stock

Aratana Therapeutics, Inc. (NASDAQ:PETX) major shareholder Healthcare Master Fun Broadfin sold 890,516 shares of the stock in a transaction that occurred on Friday, December 1st. The shares were sold at an average price of $5.70, for a total transaction of $5,075,941.20. The sale was disclosed in a filing with the SEC, which is available at this link. Large shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Healthcare Master Fun Broadfin also recently made the following trade(s):

  • On Wednesday, November 29th, Healthcare Master Fun Broadfin sold 116,516 shares of Aratana Therapeutics stock. The stock was sold at an average price of $6.53, for a total value of $760,849.48.

Shares of Aratana Therapeutics, Inc. (PETX) opened at $5.45 on Friday. Aratana Therapeutics, Inc. has a twelve month low of $4.97 and a twelve month high of $8.63. The company has a quick ratio of 3.08, a current ratio of 3.42 and a debt-to-equity ratio of 0.26.

Aratana Therapeutics (NASDAQ:PETX) last released its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($0.21) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.24) by $0.03. The business had revenue of $6.16 million during the quarter, compared to the consensus estimate of $6.47 million. Aratana Therapeutics had a negative return on equity of 48.79% and a negative net margin of 358.55%. The business’s quarterly revenue was up 1440.0% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.38) EPS. sell-side analysts predict that Aratana Therapeutics, Inc. will post -1.03 EPS for the current fiscal year.

Several institutional investors have recently added to or reduced their stakes in the business. Janus Henderson Group PLC lifted its position in shares of Aratana Therapeutics by 0.6% during the 3rd quarter. Janus Henderson Group PLC now owns 1,801,381 shares of the biopharmaceutical company’s stock valued at $11,042,000 after buying an additional 10,551 shares in the last quarter. Alyeska Investment Group L.P. lifted its position in shares of Aratana Therapeutics by 10.5% during the 3rd quarter. Alyeska Investment Group L.P. now owns 964,116 shares of the biopharmaceutical company’s stock valued at $5,910,000 after buying an additional 91,763 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Aratana Therapeutics by 2.0% during the 3rd quarter. Dimensional Fund Advisors LP now owns 388,437 shares of the biopharmaceutical company’s stock valued at $2,381,000 after buying an additional 7,542 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of Aratana Therapeutics by 20.8% during the 3rd quarter. Wells Fargo & Company MN now owns 367,365 shares of the biopharmaceutical company’s stock valued at $2,252,000 after buying an additional 63,377 shares in the last quarter. Finally, Cadence Capital Management LLC lifted its position in shares of Aratana Therapeutics by 5.1% during the 3rd quarter. Cadence Capital Management LLC now owns 173,808 shares of the biopharmaceutical company’s stock valued at $1,065,000 after buying an additional 8,449 shares in the last quarter. Institutional investors and hedge funds own 73.95% of the company’s stock.

A number of brokerages recently commented on PETX. Zacks Investment Research lowered Aratana Therapeutics from a “buy” rating to a “hold” rating in a research note on Saturday, November 18th. HC Wainwright assumed coverage on Aratana Therapeutics in a research report on Friday, November 17th. They issued a “buy” rating and a $10.00 price target for the company. Jefferies Group set a $9.00 price target on Aratana Therapeutics and gave the stock a “buy” rating in a research report on Thursday, November 16th. BidaskClub lowered Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, August 8th. Finally, ValuEngine lowered Aratana Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $8.75.

COPYRIGHT VIOLATION NOTICE: “Healthcare Master Fun Broadfin Sells 890,516 Shares of Aratana Therapeutics, Inc. (PETX) Stock” was originally published by Community Financial News and is the property of of Community Financial News. If you are viewing this news story on another site, it was illegally copied and republished in violation of US & international copyright and trademark laws. The original version of this news story can be viewed at https://www.com-unik.info/2017/12/03/healthcare-master-fun-broadfin-sells-890516-shares-of-aratana-therapeutics-inc-petx-stock.html.

About Aratana Therapeutics

Aratana Therapeutics, Inc is a pet therapeutics company focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets.

Insider Buying and Selling by Quarter for Aratana Therapeutics (NASDAQ:PETX)

What are top analysts saying about Aratana Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Aratana Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit